Hadassah

Thrombotech Receives Regulatory Approval for Stroke Medicine Trials in the US

Wednesday, Mar 28 2012

Thrombotech Ltd., a biotechnology company based on cutting-edge stroke research at the Hadassah University Medical Center, has received approval from the United States' Food and Drug Administration (FDA) to expand clinical trials to the US for its lead product, THR-18. This medicine is designed to improve the safety and efficacy of tPA, the currently available treatment for ischemic stroke.

THR-18 is designed to allow tPA to dissolve blood clots easily, extending its short therapeutic time window and diminishing life-threatening side effects. It is currently undergoing Phase IIA clinical trials at several hospitals in Israel, including Hadassah, and is awaiting regulatory approvals in Europe and India.

"This important regulatory approval serves as external validation for our development program and the quality of the science and management behind the company," says Thrombotech Chief Executive Officer Dr. Ruth Ben Yakar. "It will enable us to recruit more patients in some of the leading medical centers specializing in stroke in the US and move towards commercialization of the therapy for this serious medical condition."

Hadasit, Hadassah's technology transfer company, holds a 24% stake in Thrombotech. Commenting on the approval, Ophir Shahaf, Chief Executive Officer of Hadasit Bio-Holdings, Hadasit's publicly traded subsidiary, stated: "We are proud to expand the clinical trial to medical centers in the US, a world leader in Central Nervous System therapeutics and stroke treatment in particular."

Related Stories

alt_text

Monday, Sep 16 2019

Hadassah Australia Will Help Ethiopian Israelis Achieve Their Dream

Barely 11 percent of Ethiopian Jewish students attend university in Israel, as compared to 42 percent of their counterparts in the general population.

READ MORE ›
alt_text

Friday, Sep 6 2019

An Oasis of Peace

In the Jerusalem Post, Hadassah President Ellen Hershkin writes about Middle East peace, shared society and dignity for all.

READ MORE ›
alt_text

Friday, Sep 6 2019

New, Larger Pediatric Bone Marrow Transplant Unit Opens at Hadassah

With a $4.75-million grant from The Leona M. and Harry B. Helmsley Charitable Trust, the Hadassah Medical Organization has opened a new pediatric bone marrow transplantation...

READ MORE ›
alt_text

Friday, Sep 6 2019

Creating an Exceptional Bar Mitzvah Experience

Thirty members of the Moises Jafif family from Mexico, along with their friends, came to Israel to celebrate the Bar Mitzvah of Jak Jafif at the Kotel (the western wall of the ancient Temple Mount).

READ MORE ›
SUPPORT HADASSAH HOSPITALS

Learn more about the Hadassah Medical Organization.

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More